USPTO Examiner WARD PAUL V - Art Unit 1624

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18606890ANTI-CANCER COMPOSITION CONTAINING GOLD AND CYTOTOXIC AGENTMarch 2024August 2024Allow501NoNo
18606917CYTOTOXICITY ASSAY COMPOSITION AND GOLD (III) COMPLEXMarch 2024August 2024Allow501NoNo
18606361LIQUID PHARMACEUTICAL COMPOSITION OF GOLDMarch 2024August 2024Allow501NoNo
18606260SOLID PHARMACEUTICAL GOLD-BASED COMPOSITIONMarch 2024July 2024Allow501NoNo
18534330ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOBENZENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)Cl (PiPr3)2 MOIETIES AS AN INORGANIC CATALYSTDecember 2023February 2024Allow200NoNo
183826961-(4-NITROBENZYLIDENEAMINO)-5-PHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow301NoNo
184843952-ALKOXY[4,3:6,4-TERPYRIDINE]-3-CARBONITRILES AS ANTIMICROBIAL COMPOUNDSOctober 2023January 2024Allow401NoNo
18459778USE OF TAPINAROF FOR THE TREATMENT OF ATOPIC DERMATITISSeptember 2023February 2024Allow511NoNo
18132241POLYMORPHS OF SELINEXORApril 2023July 2023Allow300YesNo
18131273POLYMORPHS OF SELINEXORApril 2023July 2023Allow310NoNo
18069886METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASEDecember 2022June 2024Abandon1710NoNo
18085467NEUTROPHIL SUPPRESSION AS PRECONDITIONING TO INCREASE ONCOLYTIC BACTERIAL THERAPYDecember 2022July 2024Allow1811NoNo
18057505NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDERNovember 2022May 2024Allow1711NoNo
17938531METHODS OF USING PROTEIN PALMITOYLATIONS INHIBITORSOctober 2022July 2024Allow2111NoNo
17944963INHIBITORS OF FIBROBLAST ACTIVATION PROTEINSeptember 2022May 2024Abandon2001NoNo
17896558SYSTEM AND ASSAY FOR MONITORING PRODUCTION/RELEASE OF MEMBRANE-LYTIC TOXINS IN BACTERIA AND COMPOUNDS FOR MODULATING SAMEAugust 2022April 2024Allow2011NoNo
17820667SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USEAugust 2022April 2024Allow2010NoNo
17886075C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USINGAugust 2022March 2024Allow2011NoNo
17882046NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODSAugust 2022November 2022Allow301YesNo
17871178DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERSJuly 2022April 2024Abandon2110NoNo
17871663USE OF TAPINAROF FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASISJuly 2022January 2023Allow620NoNo
17861809BIARYLMETHYL HETEROCYCLESJuly 2022January 2024Allow1801NoNo
17860884TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITORJuly 2022December 2022Allow610NoNo
17857478THERAMUTEIN MODULATORSJuly 2022November 2023Allow1610NoNo
17857492THERAMUTEIN MODULATORSJuly 2022July 2023Allow1300NoNo
17854443JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CHRONIC LUNG ALLOGRAFT DYSFUNCTIONJune 2022September 2023Allow1510NoNo
17789874High Triplet Yield Phenothiazine Donor-Acceptor Complexes For Photoredox CatalysisJune 2022November 2023Allow1601YesNo
17849784CAMSYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVESJune 2022December 2023Allow1811NoNo
17789474METHOD FOR PREPARING DIAZOXIDEJune 2022January 2024Allow1911NoNo
17843587METHOD OF CONTROLLING BLOOD SUGAR LEVEL AND TREATMENT OF DIABETES AND RELATED CONDITIONSJune 2022March 2024Abandon2111NoNo
17836444COMBINATION MCL-1 INHIBITORS WITH ANTI-CANCER AGENTSJune 2022October 2023Allow1611NoNo
17830682CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENTJune 2022October 2023Allow1611NoNo
17831049Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic DiseasesJune 2022December 2023Allow1801NoNo
17804897METHOD FOR CONTROLLING FUSARIUM OXYSPORUM F. SP. CUBENSE TROPICAL RACE 4June 2022October 2023Allow1610YesNo
17828983COMPOSITION AND METHOD FOR TREATING A DRUG-RESISTANT CANCERMay 2022December 2023Allow1911NoNo
17826061COMPOUNDS FOR THE TREATMENT OF SARSMay 2022October 2023Allow1711NoNo
17825019ALKYL-TERMINATED THIOCARBAMATE COMPLEX AND METHOD FOR TREATING CANCERMay 2022February 2024Allow2111NoNo
17825009ALKYL AMINE DITHIOCARBAMATE GOLD COMPLEX FOR CANCER TREATMENTMay 2022February 2024Allow2111NoNo
17751226KINASE MUTATION-ASSOCIATED NEURODEGENERATIVE DISORDERSMay 2022December 2023Allow2310NoNo
17747754THERAPEUTIC COMPOUNDS AND USES THEREOFMay 2022February 2024Abandon2101NoNo
17745924NOVEL SUBSTITUTED TETRAHYDROISOQUINOLINES AS ANTI-MITOTIC DRUG IN TRIPLE NEGATIVE BREAST CANCERMay 2022October 2023Allow1720NoNo
17745045METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTICMay 2022October 2023Allow1711NoNo
17741162COMPOSITION OF PHYTONUTRIENTS FOR DIABETES MANAGEMENTMay 2022May 2024Abandon2511NoNo
17734345COMBINATION THERAPYMay 2022February 2024Abandon2110NoNo
17723598METHODS OF REDUCING THE RISK OF HEART FAILUREApril 2022December 2023Allow2011NoNo
17716156COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASEApril 2022March 2024Allow2311NoNo
17699693METHOD OF PROMOTING ANTITUMOR OR ANTI-CANCER IMMUNITYMarch 2022February 2024Allow2311YesNo
17697448COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONSMarch 2022August 2022Allow520NoNo
17694635COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVESMarch 2022August 2023Allow1700NoNo
17653982METHODS FOR TREATING OCULAR SURFACE PAINMarch 2022January 2024Abandon2210NoNo
17653256CARBOXYLIC ACID COMPOUNDSMarch 2022April 2024Allow2601NoNo
17681387SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITYFebruary 2022August 2023Allow1801NoNo
17679113APPLICATIONS OF ELLAGIC ACID IN PREPARATION OF IMMUNOMODULATORY MEDICINES FOR TREATMENT OF NEUROMYELITIS OPTICA OR IMMUNE REJECTION AFTER SKIN TRANSPLANTATIONFebruary 2022January 2024Allow2211NoNo
17586515LIPID PRODRUGS OF MYCOPHENOLIC ACID AND USES THEREOFJanuary 2022August 2023Allow1910NoNo
17576128CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOFJanuary 2022May 2022Allow411NoNo
17571352PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSYJanuary 2022April 2023Allow1500NoNo
17564446QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERSDecember 2021February 2024Abandon2601NoNo
17554375CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOFDecember 2021February 2024Abandon2610NoNo
17551105KIF18A INHIBITORSDecember 2021March 2024Allow2711NoNo
17527544PREPARATION METHOD OF SELENIUM-CONTAINING HETEROCYCLIC COMPOUNDSNovember 2021October 2022Allow1101NoNo
17520499Immunosuppressant Comprising TSAHC or a Pharmaceutically Acceptable Salts Thereof as an Active IngredientNovember 2021April 2024Allow2910NoNo
17516542DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORSNovember 2021June 2024Abandon3111NoNo
17506497NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONISTOctober 2021April 2024Allow3011NoNo
17501075COMPOUNDS THAT INHIBIT MCL-1 PROTEINOctober 2021February 2024Allow2811NoNo
17450254SYNTHETIC ROUTE TO SCOPOLAMINE AND/OR ATROPINEOctober 2021April 2023Allow1801NoNo
17494458RORGAMMA MODULATORS AND USES THEREOFOctober 2021January 2024Allow2711YesNo
17490778METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIESSeptember 2021April 2024Allow3011YesNo
17478451HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITORSeptember 2021January 2024Abandon2801NoNo
17465087MODULATORS OF AIRWAY BASAL CELLS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASESSeptember 2021April 2024Allow3120NoNo
17462148N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDSAugust 2021December 2023Allow2711YesNo
17460775INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTIONAugust 2021December 2021Allow410YesNo
17461695PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASEAugust 2021November 2023Allow2611NoNo
17459889Orally Administrated Therapeutic for Treating Mild Cognitive Impairment (MCI) and Improving Human Cognitive FunctionAugust 2021October 2023Allow2610NoNo
17404800Chlorin Derivatives or Pharmaceutically Acceptable Salts Thereof, Preparation Method and Use Thereof, and Combination Thereof with an Ultrasonic Medical SystemAugust 2021February 2024Allow3011NoNo
17398801Pharmaceutical Compositions Having Improved Storage StabilityAugust 2021December 2023Allow2821NoNo
17396223ANTIMICROBIAL COMPOSITIONS AND RELATED METHODSAugust 2021June 2024Allow3411NoNo
17395723Compounds Useful in HIV TherapyAugust 2021August 2023Allow2410NoNo
17391081ANTIVIRAL AGENTSAugust 2021March 2023Abandon1901NoNo
17387888REAGENTS FOR QUANTITATIVE MASS SPECTROMETRYJuly 2021January 2024Allow3011NoNo
17443264NUCLEAR RECEPTOR MODULATORSJuly 2021January 2024Abandon2901NoNo
17380865Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses ThereofJuly 2021March 2023Abandon1901NoNo
17380943PTPN11 INHIBITORSJuly 2021November 2023Allow2811NoNo
17377885RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATIONJuly 2021August 2023Allow2510NoNo
17365656POLYMORPHS OF SELINEXORJuly 2021June 2023Allow2310NoNo
17363534ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USEJune 2021July 2024Abandon3611NoNo
17364039ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOFJune 2021March 2023Abandon2001NoNo
17356305CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITHJune 2021April 2023Allow2101NoNo
17355792SYNTHESIS OF COELENTERAZINE SYNTHESIS INTERMEDIATEJune 2021July 2023Allow2510YesNo
17354322CHEMICAL COMPOUNDSJune 2021June 2023Allow2411NoNo
17349584PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVEJune 2021May 2023Allow2310NoNo
17342873POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORSJune 2021January 2024Allow3111NoNo
17341312ADMINISTRATION OF BERBERINE METABOLITESJune 2021December 2023Allow3011YesNo
17337006COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMSJune 2021July 2023Allow2610YesNo
17336444METALLOENZYME INHIBITOR COMPOUNDSJune 2021November 2023Allow2911NoNo
17334166POLYMERIC METAL CHELATING COMPOSITIONS AND METHODS OF PREPARING SAME FOR CONTROLLING GROWTH AND ACTIVITIES OF LIVING CELLS AND ORGANISMS FOR THERAPEUTIC USE IN TREATING DISEASES IN ANIMALS, FISH OR HUMANSMay 2021December 2023Allow3120NoNo
17325968COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONSMay 2021February 2022Allow920NoNo
173234823-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTEROPIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAMEMay 2021July 2023Allow2610NoNo
17318772CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALTMay 2021October 2021Allow510NoNo
17318876CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALTMay 2021October 2021Allow510NoNo
17318677CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALTMay 2021October 2021Allow510NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WARD, PAUL V.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
2
(66.7%)
Examiner Reversed
1
(33.3%)
Reversal Percentile
48.2%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
39
Allowed After Appeal Filing
15
(38.5%)
Not Allowed After Appeal Filing
24
(61.5%)
Filing Benefit Percentile
60.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 38.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner WARD, PAUL V - Prosecution Strategy Guide

Executive Summary

Examiner WARD, PAUL V works in Art Unit 1624 and has examined 1,585 patent applications in our dataset. With an allowance rate of 75.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.

Allowance Patterns

Examiner WARD, PAUL V's allowance rate of 75.5% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by WARD, PAUL V receive 1.09 office actions before reaching final disposition. This places the examiner in the 16% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WARD, PAUL V is 22 months. This places the examiner in the 79% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -25.2% benefit to allowance rate for applications examined by WARD, PAUL V. This interview benefit is in the 0% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 44.1% of applications are subsequently allowed. This success rate is in the 95% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 75.9% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 89.3% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 88.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 57.5% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.0% of allowed cases (in the 77% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 25.7% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.